Halozyme Therapeutics Inc (HALO) Common Stock USD0.001

Sell:$61.88Buy:$61.91$0.93 (1.48%)

NASDAQ:5.97%
Market closed | Prices delayed by at least 15 minutes
Sell:$61.88
Buy:$61.91
Change:$0.93 (1.48%)
Deal now
Market closed | Prices delayed by at least 15 minutes
Sell:$61.88
Buy:$61.91
Change:$0.93 (1.48%)
Market closed | Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and Idorsia Pharmaceuticals.

Key people

Helen I. Torley
President, Chief Executive Officer, Director
Nicole Labrosse
Chief Financial Officer, Senior Vice President
Mark Snyder
Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
Jeffrey W. Henderson
Independent Chairman of the Board
Bernadette M. Connaughton
Independent Director
Barbara Duncan
Independent Director
Mahesh Krishnan
Independent Director
Connie L. Matsui
Independent Director
Click to see more

Key facts

  • EPIC
    HALO
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US40637H1095
  • Market cap
    $7.64bn
  • Employees
    350
  • Shares in issue
    123.53m
  • Exchange
    NASDAQ
  • Index
    S&P 400 Mid Cap, TR Equity United States Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.